Have a feature idea you'd love to see implemented?
Let us know!
CRSP CRISPR Therapeutics AG
Price (delayed)
$47.95
Market cap
$4.08B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$3.82B
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that
Highlights
The debt has declined by 6% year-on-year
The EPS is up by 40% year-on-year but it has declined by 19% since the previous quarter
The company's net income rose by 36% YoY but it fell by 22% QoQ
Key stats
What are the main financial stats of CRSP
Market
Valuations
Earnings
Shares outstanding
85.17M
Market cap
$4.08B
Enterprise value
$3.82B
Price to book (P/B)
2.06
Price to sales (P/S)
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.89
Revenue
$202.23M
EBIT
-$263.15M
EBITDA
-$243.65M
Free cash flow
-$126.04M
Per share
Balance sheet
Liquidity
EPS
-$3.2
Free cash flow per share
-$1.48
Book value per share
$23.33
Revenue per share
$2.38
TBVPS
$27.55
Total assets
$2.34B
Total liabilities
$358.9M
Debt
$231.3M
Equity
$1.98B
Working capital
$1.88B
Debt to equity
0.12
Current ratio
15.73
Quick ratio
15.75
Net debt/EBITDA
1.09
Margins
Efficiency
Dividend
EBITDA margin
-120.5%
Gross margin
100%
Net margin
-131.4%
Operating margin
-175.4%
Return on assets
-11.7%
Return on equity
-13.9%
Return on invested capital
-14.2%
Return on capital employed
-11.9%
Return on sales
-130.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRSP stock price
How has the CRISPR Therapeutics AG stock price performed over time
Intraday
4.24%
1 week
-0.7%
1 month
2.48%
1 year
15.51%
YTD
-23.4%
QTD
2.06%
Financial performance
How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$202.23M
Gross profit
$202.23M
Operating income
-$354.68M
Net income
-$265.8M
Gross margin
100%
Net margin
-131.4%
The net margin has dropped by 64% since the previous quarter but it has increased by 46% year-on-year
The operating margin has dropped by 60% since the previous quarter but it is up by 37% year-on-year
The company's net income rose by 36% YoY but it fell by 22% QoQ
The company's gross profit fell by 26% QoQ but it rose by 19% YoY
Growth
What is CRISPR Therapeutics AG's growth rate over time
Valuation
What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
2.06
P/S
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.89
The EPS is up by 40% year-on-year but it has declined by 19% since the previous quarter
The price to book (P/B) is 36% lower than the 5-year quarterly average of 3.2 and 14% lower than the last 4 quarters average of 2.4
The equity has increased by 9% YoY but it has decreased by 4.9% QoQ
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 1365.7 but 3.8% higher than the last 4 quarters average of 19.4
The revenue has declined by 26% since the previous quarter but it has grown by 19% year-on-year
Efficiency
How efficient is CRISPR Therapeutics AG business performance
The return on sales has dropped by 64% since the previous quarter but it is up by 48% year-on-year
The ROE has grown by 37% YoY but it has contracted by 20% from the previous quarter
The company's return on assets rose by 36% YoY but it fell by 21% QoQ
The ROIC rose by 34% YoY but it fell by 21% QoQ
Dividends
What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRSP.
Financial health
How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is up by 13% YoY but it is down by 12% QoQ
CRISPR Therapeutics AG's current ratio has increased by 12% YoY but it has decreased by 12% from the previous quarter
The debt is 88% smaller than the equity
CRSP's debt to equity is down by 14% YoY but it is up by 9% QoQ
The equity has increased by 9% YoY but it has decreased by 4.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.